OPGEN INC

OPGN OTC CIK: 0001293818

Company Information

Industry Services-Medical Laboratories
SIC Code 8071
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 9717 KEY WEST AVENUE, ROCKVILLE, MD, 20850
Mailing Address 9717 KEY WEST AVENUE, ROCKVILLE, MD, 20850
Phone 301-869-9683
Fiscal Year End 1231
EIN 061614015

Financial Overview

FY2024 FY

$5.20M
Revenue
$11.99M
Net Income
$9.86M
Total Assets
$13.44M
Total Liabilities
$1.31M
Cash & Equivalents
$2.44
EPS

Recent SEC Filings

Form Type Date Filed Document
DEF 14A Definitive proxy statement February 6, 2026 View on SEC
8-K Current report of material events January 16, 2026 View on SEC
8-K Current report of material events December 23, 2025 View on SEC
3 Initial insider ownership report December 10, 2025 View on SEC
8-K Current report of material events December 5, 2025 View on SEC
10-Q Quarterly financial report November 19, 2025 View on SEC
10-Q Quarterly financial report October 31, 2025 View on SEC
10-Q Quarterly financial report October 1, 2025 View on SEC
10-K Annual financial report August 21, 2025 View on SEC
4 Insider stock transaction report July 30, 2025 View on SEC

Material Events

8-K Acquisition January 16, 2026
High Impact
  • OPGEN is making a bold strategic move by acquiring iCapX Sdn. Bhd., propelling it into the high-growth fintech sector.
  • This acquisition marks a substantial strategic pivot, diversifying OPGEN from its traditional diagnostics business.
View Analysis
8-K Leadership Change December 5, 2025
High Impact
  • OPGEN INC executed a reverse stock split to meet NASDAQ listing requirements and improve stock perception.
  • John Tan Honjian stepped down as CEO on December 1, 2025, but will continue as Chairman of the Board.
View Analysis

Related Companies

Companies in the same industry (SIC: 8071)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.